Role for endothelin-1 in angiotensin II-mediated hypertension

Hypertension

Volumn 30, Issue 1, 1997, Pages 29-34

  Rajagopalan, Sanjay ^a   Laursen, Jørn Bech ^a,b,c   Borthayre, Alain ^a   Kurz, Sabine ^a   Keiser, Joan ^d   Haleen, Steven ^d   Giaid, Adel ^b   Harrison, David G ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c University of Copenhagen   (Denmark)

^d PFIZER INC   (United States)

Author keywords

Angiotensin II; Endothelin; Receptors

Indexed keywords

3 BENZYL 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 2 BUTENOIC ACID; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; LOSARTAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; HYPERTENSION; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; VASCULAR SMOOTH MUSCLE;

EID: 0030803530     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.30.1.29     Document Type: Article

References (28)

1. Griendling K, Alexander R. Cellular mechanisms of angiotensin II action. In: Swales J, ed. Textbook of Hypertension. 1st ed. Oxford, UK: Blackwell Scientific Publications; 1994:244-253.
2. Sung CP, Arleth AJ, Storer BL, Ohlstein EH. Angiotensin type 1 receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle. J Pharmacol Exp Ther. 1994;271:429-437.
3. Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, Marumo F. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension. 1992;19:753-757.
4. Chua BH, Chua CC, Diglio CA, Siu BB. Regulation of endothelin-1 mRNA by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta. 1993;1178:201-206.
5. Ito H, Hirata Y, Adachi S, Tanaka M, Tsujino M, Koike A, Nogami A, Murumo F, Hiroe M. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest. 1993;92:398-403.
6. Ishiye M, Umemura K, Uematsu T, Nakashima M. Angiotensin ATI receptor-mediated attenuation of cardiac hypertrophy due to volume overload: involvement of endothelin. Eur J Pharmacol. 1995;280:11-17.
7. Cozza EN, Chiou S, Gomez-Sanchez CE. Endothelin-1 potentiation of angiotensin II stimulation of aldosterone production. Am J Physiol. 1992;262:R85-R89.
8. Saito Y, Nakao K, Mukoyama M, Imura H. Increased plasma endothelin level in patients with essential hypertension. N Engl J Med. 1990;322:205. Letter.
9. Kurihara Y, Kurihara H, Suzuki H, Kodama T, Maemura K, Nagai R, Oda H, Kuwaki T, Cao WH, Kamada N, Jishage K, Ouchi Y, Azuma S, Toyoda Y, Ishikawa T, Kumada M, Yazaki Y. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature. 1994;368:703-710.
10. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman B, Griendling K, Harrison D. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
11. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart D. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732-1739.
12. Münzel T, Giaid A, Kurz S, Stewart DJ, Harrison DG. Evidence for a role of endothelin-1 and protein kinase C in nitroglycerin tolerance. Proc Natl Acad Sci U S A. 1995;92:5244-5248.
13. Doherty A, Patt W, Edmunds J, Berryman K, Ralsdorph B, Plummer M, Shahripour A, Lee C, Chang X-M, Walker D, Haleen S, Kaiser J, Flynn M, Welch K, Hallack H, Taylor D, Reynolds E. Discovery of a novel series of orally active non-peptide endothelin-A (ETA) receptor-sensitive antagonists. J Med Chem. 1995;38:1259-1263.
14. Nishikibe M, Tsuchida S, Okada M, Fukuroda T, Shimamoto K, Yano M, Ishikawa K, Ikemoto F. Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model. Life Sci. 1993;52:717-724.
15. Okada M, Fukuroda T, Shimamoto K, Takahashi R, Ikemoto F, Yano M, Nishikibe M. Antihypertensive effects of BQ-123, a selective endothelin ETA receptor antagonist, in spontaneously hypertensive rats treated with DOCA-salt. Eur J Pharmacol. 1994; 259:339-342.
16. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun. 1994;199:1461-1465.
17. Yang ZH, Richard V, von Segesser L, Bauer E, Stulz P, Turina M, Luscher TF. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries: a new mechanism of vasospasm? Circulation. 1990;82:188-195.
18. Henrion D, Laher I. Potentiation of norepinephrine-induced contractions by endothelin-1 in the rabbit aorta. Hypertension. 1993;22: 78-83.
19. Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis. 1989; 78:225-228.
20. Komuro I, Kurihara H, Sugiyama T, Yoshizumi M, Takaku F, Yazaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett. 1988;238: 249-252.
21. Puri PL, Avantaggiati ML, Burgio VL, Chirillo P, Collepardo D, Natoli G, Balsano C, Levrero M. Reactive oxygen intermediates mediate angiotensin II-induced c-Jun c-Fos heterodimer DNA binding activity and proliferative hypertrophic responses in myogenic cells. J Biol Chem. 1995;270:22129-22134.
22. Watanabe T, Suzuki N, Shimamoto N, Fujino M, Imada A. Endothelin in myocardial infarction. Nature. 1990;344:114.
23. Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G. ACE inhibitor use in patients with myocardial infarction: summary of evidence from clinical trials. Circulation. 1995;92:3132-3137.
24. Wei CM, Lerman A, Rodeheffer RJ, McGregor CG, Brandt RR, Wright S, Heublein DM, Kao PC, Edwards WD, Burnett JC Jr. Endothelin in human congestive heart failure. Circulation. 1994;89: 1580-1586.
25. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation. 1994;89: 1573-1579.
26. Acute Infarction Ramipril Efficacy Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
27. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
28. Pfeffer M, Braunwald E, Moyé L, Basta L, Brown EJ, Cuddy T, Davis B, Geltman E, Goldman S, Flaker GC, Klein M, Lamas G, Packer M, Rouleau J, Rouleau J, Rutherford J, Wertheimer J, Hawkins C, and the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327:669-677.